{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:31:58Z","timestamp":1792740718960,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00415-024-12585-w","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T15:01:41Z","timestamp":1722092501000},"page":"6160-6171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessment of international MOGAD diagnostic criteria in patients with overlapping MOG-associated disease and multiple sclerosis phenotypes"],"prefix":"10.1007","volume":"271","author":[{"given":"Giovanna S.","family":"Manzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Salky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrah J.","family":"Mateen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Klawiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja","family":"Chitnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni S.","family":"Vasileiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias S.","family":"Sotirchos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Huda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Matiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,27]]},"reference":[{"issue":"3","key":"12585_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 22(3):268\u2013282. https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"issue":"5","key":"12585_CR2","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","volume":"266","author":"R Wynford-Thomas","year":"2019","unstructured":"Wynford-Thomas R, Jacob A, Tomassini V (2019) Neurological update: MOG antibody disease. J Neurol 266(5):1280\u20131286. https:\/\/doi.org\/10.1007\/s00415-018-9122-2","journal-title":"J Neurol"},{"key":"12585_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.msard.2019.01.021","volume":"29","author":"S Salama","year":"2019","unstructured":"Salama S, Khan M, Levy M, Izbudak I (2019) Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. Mult Scler Relat Disord 29:15\u201322. https:\/\/doi.org\/10.1016\/j.msard.2019.01.021","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"12585_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.neurad.2019.06.001","volume":"46","author":"M Den\u00e8ve","year":"2019","unstructured":"Den\u00e8ve M, Biotti D, Patsoura S et al (2019) MRI features of demyelinating disease associated with anti-MOG antibodies in adults. J Neuroradiol 46(5):312\u2013318. https:\/\/doi.org\/10.1016\/j.neurad.2019.06.001","journal-title":"J Neuroradiol"},{"issue":"6","key":"12585_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","volume":"78","author":"E Sechi","year":"2021","unstructured":"Sechi E, Buciuc M, Pittock SJ et al (2021) Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol 78(6):741\u2013746","journal-title":"JAMA Neurol"},{"key":"12585_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1144-2","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflamm. https:\/\/doi.org\/10.1186\/s12974-018-1144-2","journal-title":"J Neuroinflamm"},{"key":"12585_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.947630","volume":"13","author":"GS Manzano","year":"2022","unstructured":"Manzano GS, Salky R, Mateen FJ et al (2022) Positive predictive value of MOG-IgG for clinically defined MOG-AD within a real-world cohort. Front Neurol 13:947630. https:\/\/doi.org\/10.3389\/fneur.2022.947630","journal-title":"Front Neurol"},{"key":"12585_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103746","author":"M Levy","year":"2022","unstructured":"Levy M, Yeh EA, Hawkes CH, Lechner-Scott J, Giovannoni G (2022) Implications of low-titer MOG antibodies. Mult Scler Relat Disord. https:\/\/doi.org\/10.1016\/j.msard.2022.103746","journal-title":"Mult Scler Relat Disord"},{"key":"12585_CR9","doi-asserted-by":"publisher","unstructured":"Messina S, Mariano R, Roca-Fernandez A, et al (2021) Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis. Mult Scler J. https:\/\/journals.sagepub.com\/doi\/https:\/\/doi.org\/10.1177\/13524585211018987?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed. Accessed July 16, 2021","DOI":"10.1177\/13524585211018987?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed"},{"issue":"3","key":"12585_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","volume":"76","author":"D Dubey","year":"2019","unstructured":"Dubey D, Pittock SJ, Krecke KN et al (2019) Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 76(3):301\u2013309","journal-title":"JAMA Neurol"},{"issue":"4","key":"12585_CR11","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2214\/AJR.20.24061","volume":"216","author":"M Shahriari","year":"2021","unstructured":"Shahriari M, Sotirchos ES, Newsome SD, Yousem DM (2021) MOGAD: How it differs from and resembles other neuroinflammatory disorders. AJR Am J Roentgenol 216(4):1031\u20131039. https:\/\/doi.org\/10.2214\/AJR.20.24061","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"12585_CR12","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1212\/WNL.0000000000201465","volume":"100","author":"R Cortese","year":"2023","unstructured":"Cortese R, Prados Carrasco F, Tur C et al (2023) Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder and MOG-antibody disease with imaging. Neurology 100(3):e308\u2013e323. https:\/\/doi.org\/10.1212\/WNL.0000000000201465","journal-title":"Neurology"},{"key":"12585_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.msard.2018.08.008","volume":"25","author":"C Bensi","year":"2018","unstructured":"Bensi C, Marrodan M, Gonz\u00e1lez A et al (2018) Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis. Mult Scler Relat Disord 25:246\u2013250","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"12585_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/brain\/aww350","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Geraldes R, Probert F et al (2017) Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain J Neurol 140(3):617\u2013627. https:\/\/doi.org\/10.1093\/brain\/aww350","journal-title":"Brain J Neurol"},{"key":"12585_CR15","doi-asserted-by":"crossref","unstructured":"Sechi, Elia, Krecke, Karl N., Messina, Steven A., et al (2021) Comparison of MRI lesion evolution in different central nervous system demyelinating disorders. Neurology. https:\/\/n.neurology.org\/content\/97\/11\/e1097. Accessed October 8, 2021","DOI":"10.1212\/WNL.0000000000012467"},{"issue":"2","key":"12585_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"issue":"6","key":"12585_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82(6):474\u2013481. https:\/\/doi.org\/10.1212\/WNL.0000000000000101","journal-title":"Neurology"},{"key":"12585_CR18","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000089","author":"P Waters","year":"2015","unstructured":"Waters P, Woodhall M, O\u2019Connor KC et al (2015) MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000089","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"12585_CR19","doi-asserted-by":"publisher","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","volume":"92","author":"PJ Waters","year":"2019","unstructured":"Waters PJ, Komorowski L, Woodhall M et al (2019) A multicenter comparison of MOG-IgG cell-based assays. Neurology 92(11):e1250\u2013e1255. https:\/\/doi.org\/10.1212\/WNL.0000000000007096","journal-title":"Neurology"},{"issue":"11","key":"12585_CR20","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1177\/13524585221093789","volume":"28","author":"G Fadda","year":"2022","unstructured":"Fadda G, Waters P, Woodhall M et al (2022) Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria. Mult Scler Houndmills Basingstoke Engl 28(11):1697\u20131709. https:\/\/doi.org\/10.1177\/13524585221093789","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"12","key":"12585_CR21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/jamaneurol.2023.3956","volume":"80","author":"P Lipps","year":"2023","unstructured":"Lipps P, Ayroza Galv\u00e3o Ribeiro Gomes AB, Kulsvehagen L et al (2023) Ongoing challenges in the diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 80(12):1377\u20131379. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3956","journal-title":"JAMA Neurol"},{"issue":"1","key":"12585_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","volume":"14","author":"P Peschl","year":"2017","unstructured":"Peschl P, Schanda K, Zeka B et al (2017) Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflamm 14(1):208. https:\/\/doi.org\/10.1186\/s12974-017-0984-5","journal-title":"J Neuroinflamm"},{"issue":"5","key":"12585_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000257","volume":"3","author":"M Spadaro","year":"2016","unstructured":"Spadaro M, Gerdes LA, Krumbholz M et al (2016) Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3(5):e257. https:\/\/doi.org\/10.1212\/NXI.0000000000000257","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12585_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000649","author":"\u00c1 Cobo-Calvo","year":"2020","unstructured":"Cobo-Calvo \u00c1, d\u2019Indy H, Ruiz A et al (2020) Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: a multicenter cross-sectional study. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000649","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12585_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.msard.2019.05.021","volume":"33","author":"M Breza","year":"2019","unstructured":"Breza M, Koutsis G, Tzartos JS et al (2019) MOG antibody-associated demyelinating disease mimicking typical multiple sclerosis: a case for expanding anti-MOG testing? Mult Scler Relat Disord 33:67\u201369. https:\/\/doi.org\/10.1016\/j.msard.2019.05.021","journal-title":"Mult Scler Relat Disord"},{"issue":"22","key":"12585_CR26","doi-asserted-by":"publisher","first-page":"e2302","DOI":"10.1212\/WNL.0000000000009239","volume":"94","author":"E Martinez-Hernandez","year":"2020","unstructured":"Martinez-Hernandez E, Guasp M, Garc\u00eda-Serra A et al (2020) Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology 94(22):e2302\u2013e2310. https:\/\/doi.org\/10.1212\/WNL.0000000000009239","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12585-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12585-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12585-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T12:24:08Z","timestamp":1725539048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12585-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,27]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["12585"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12585-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,27]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GSM, RS, ESV, EG, SH, and AJ report no disclosures. ML receives personal compensation from Alexion, Horizon, Genentech\/Roche, Sanofi, and UCB for work on advisory boards, and his lab receives grant funding from Alexion, Horizon, Genentech\/Roche, and Bluerock. FJM has received research funding support from Biogen, EMD Serono, Genentech, the Sumaira Foundation, the National MS Society, and NIH. She has received personal consulting fees from Genentech and Horizon Therapeutics. ECK has received consulting fees from Banner Life Sciences, Galen\/Atlantica, Genentech, and Greenwich Biosciences. ECK has received research funds from Abbvie, Biogen, and Genentech. TC has received compensation for consulting from Biogen, Novartis Pharmaceuticals, Roche Genentech, and Sanofi Genzyme, and research support from the National Institutes of Health, National MS Society, US Department of Defense, Sumaira Foundation, Brainstorm Cell Therapeutics,\u00a0EMD Serono, I-Mab Biopharma, Mallinckrodt ARD, Novartis Pharmaceuticals, Octave Bioscience, Roche Genentech, and Tiziana Life Sciences.\u00a0ESS has received speaker honoraria from Viela Bio and Biogen, and has served on scientific advisory boards for Alexion, Viela Bio and Genentech. MM has served on scientific advisory boards for Genentech, Viela Bio, TerumoBCT, Alexion, and Ipsen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}